Failure of Soluble Prednisolone Hemisuccinate to Inhibit Local Inflammation on Local Injection1  by Goldman, Leon & Barnett, Sheldon M
PRELIMINARY AND SHORT REPORT
FAILURE OF SOLUBLE PREDNISOLONE HEMISUCCINATE TO INHIBIT LOCAL
INFLAMMATION ON LOCAL INJECTION*
LEON GOLDMAN, M.D. AND SHELDON M. BAENETT, M.D.
To inhibit inflammation, the hydrocortisones and some analogs of hydroeortisone may
be used locally by injection in the skin of man. These materials are relatively insoluble in
body fluids and tissues. Soluble hydrocortisone hemisuceinate and prednisolone hemisuc-
cinate have been developed especially for intravenous use (1), and recently, a soluble hydro-
cortisone, hydrocortisone diethylaminoacetate hydrochloride has been proposed for topical
use by Robinson, Strahan and Robinson (2).
In our experience, hydrocortisone hemisuccinate and prednisolone hemisuccinate given
intravenously have been highly effective in the therapy of selected severe dermatological
disorders usually treated by systemic corticosteroid therapy (1). Prednisolone hemisuc-
cinate is more useful because of the lesser degree of metabolic reactions encountered.
It was decided to subject prednisolone hemisuccinate (Meticortelone Soluble) to assay
technics developed previously to determine local activity of a corticosteroid (3).
Standard tuberculin-type responses were induced in 14 patients by the local injection of
oidiomycin. Controls included oidiomycin alone, and oidiomycin together with hydro-
cortisone-t-butyl acetate. In all instances, there was no inhibition of inflammation by the
prednisolone hemisuccinate. In each experiment, there was a significant inhibition by
hydrocortisone-t-butyl acetate. There were two additional patients with positive tuber-
culin tests, P.P.D. No. 1, and one patient with a positive Frei test. In these three patients,
no blocking was found with prednisolone hemisuccinate, and effective blocking was ob-
tained with hydrocortisone-t-butyl acetate. In five patients with psoriasis, and seven with
so-called localized neurodermatitis, injection of 2.5—5.0 mgs. of prednisolone hemisuccinate
into the affected areas did not produce any change in the local injected site, whereas, the
characteristic local reduction of the lesion was found with the control injections of hydro-
cortisone-t-butyl acetate (3). Prednisolone hemisoccinate on local injection did not block
the local histamin reaction. In all these experiments, only freshly prepared solutions of the
soluble prednisolone hemisuccinate were used. Portions of solution of prednisolone hemisuc-
cinate were effective when given intravenously for bullous erythema multiforme and for
severe drug reactions. We have not done, as yet, any extensive controlled clinical experi-
ments with ointments containing this soluble metisteroid. In three patients, local injection
of soluble Sodium Prednisolone Phosphate did not block local reactions with oidiomycin and
histamin. Controlled clinical studies have been started with creams and lotions containing
Sodium Prednisolone Phosphate.
Biopsy studies of areas injected with prednisolone hemisuccinate at varying time limits
did not reveal crystals or lesions with characteristic hematoxylinophilic masses (3, 4).
Partition paper chromatography of prednisolone hemisuccinate was limited to skin biopsies
only after intravenous use (5). All these studies with local injections suggest that this
soluble metisteroid is absorbed so rapidly from the local site of injection that there is no
noticeable effect on local inflammation.
* From The Department of Dermatology of the College of Medicine of The University of
Cincinnati, Cincinnati, Ohio.
Work done under grant from U. S. Public Health Service A-260C3. Meticortelone Soluble
and Sodium Prednisolone Phosphate furnished by Dr. Harry V. Pifer, Medical Division,
Schering Corporation, Bloomfield, New Jersey.
Received for publication December 29, 1950.
269
270 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
SUMMARY
Soluble prednisolone hemisuccinate, although highly effective intravenously in severe
dermatologic reactions, is ineffective when injected locally to inhibit inflammation.
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